MedinCell S.A.

ENXTPA:MEDCL Stock Report

Market Cap: €491.1m

MedinCell Future Growth

Future criteria checks 5/6

MedinCell is forecast to grow earnings and revenue by 115.4% and 62.5% per annum respectively while EPS is expected to grow by 114.1% per annum.

Key information

115.4%

Earnings growth rate

114.1%

EPS growth rate

Pharmaceuticals earnings growth16.1%
Revenue growth rate62.5%
Future return on equityn/a
Analyst coverage

Low

Last updated18 Dec 2024

Recent future growth updates

Recent updates

MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be

Jul 05
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be

Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%

Apr 26
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%

Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher

Jan 09
Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher

The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On

Mar 02
The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On

Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?

Jan 08
Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?

Earnings and Revenue Growth Forecasts

ENXTPA:MEDCL - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027833937292
3/31/20263910865
3/31/202522-16-3-63
9/30/202413-312021N/A
6/30/202413-2835N/A
3/31/202412-25-13-12N/A
12/31/202313-26-18-17N/A
9/30/202314-26-24-23N/A
6/30/202314-29-23-22N/A
3/31/202314-32-22-21N/A
12/31/202213-29-22-21N/A
9/30/202212-27-22-20N/A
6/30/202210-26-23-21N/A
3/31/20228-25-23-21N/A
12/31/20219-22-21-19N/A
9/30/20219-20-18-17N/A
6/30/20219-19-15-14N/A
3/31/20218-19-13-12N/A
12/31/20207-22-12-11N/A
9/30/20205-26-11-10N/A
6/30/20206-25-12-11N/A
3/31/20206-24-13-13N/A
12/31/20196-21-16-16N/A
9/30/20196-19-19-19N/A
6/30/20195-19-18-17N/A
3/31/20194-20-17-16N/A
12/31/20186-17-12-11N/A
9/30/20187-15-8-7N/A
6/30/20188-12N/A-6N/A
3/31/20188-10N/A-5N/A
3/31/201710-4N/A-3N/A
3/31/201691N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDCL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).

Earnings vs Market: MEDCL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MEDCL is expected to become profitable in the next 3 years.

Revenue vs Market: MEDCL's revenue (62.5% per year) is forecast to grow faster than the French market (5.5% per year).

High Growth Revenue: MEDCL's revenue (62.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MEDCL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MedinCell S.A. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexandru CogutBryan Garnier & Co
Oscar Haffen LammBryan Garnier & Co
Raghuram SelvarajuH.C. Wainwright & Co.